Integra CEO awarded 343K restricted stock units

Poul Mojdeh reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Poul Mojdeh reported acquisition or exercise transactions in this Form 4 filing.

INTEGRA LIFESCIENCES HOLDINGS CORP reported that President & CEO Poul Mojdeh received a grant of 343,393 restricted stock units tied to common stock. The award vests in three equal annual installments on the first, second, and third anniversaries of the March 11, 2026 grant date.

The units are structured as deferred compensation, to be delivered within 30 days after the first business day following six months after her separation of service. Vesting may accelerate if employment ends due to death, disability, or a qualifying termination within 24 months after a change in control. Following this grant, her reported holdings in this RSU award total 445,691 units.

Insider Trade Summary

Grant/Award: 343,393 shares

Grant/Award 1 txn

Insider Poul Mojdeh

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units	343,393	$0.00	$0.00

Holdings After Transaction: Restricted Stock Units — 445,691 contracts (Direct)

Footnotes (1)

1. F1. The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2026 and which shall be delivered to Ms. Poul within 30 days following the first business day that occurs immediately following the six month period after the date of her separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Integra LifeSciences (IART) report for Poul Mojdeh?

Integra LifeSciences reported a grant of 343,393 restricted stock units to President & CEO Poul Mojdeh. These units are a form of deferred equity compensation that will convert into common stock, subject to multi-year vesting and specific employment and change-in-control conditions.

What is the vesting schedule for Poul Mojdeh’s new Integra (IART) restricted stock units?

The 343,393 restricted stock units will vest in three equal annual installments. Vesting occurs on the first, second, and third anniversaries of the March 11, 2026 grant date, assuming continued service, with potential acceleration upon certain termination or change-in-control events described in the award terms.

When will Poul Mojdeh actually receive Integra (IART) shares from this RSU award?

Shares from this restricted stock unit award will be delivered as deferred compensation after her employment ends. Delivery occurs within 30 days following the first business day immediately after six months from her separation of service, once vested units are payable in common stock.

Under what conditions can Poul Mojdeh’s Integra (IART) RSUs vest earlier than scheduled?

The award provides for accelerated vesting in several circumstances. Vesting may accelerate if her employment ends due to death or disability, or upon a qualifying termination occurring on or within 24 months following the date of a change in control of Integra LifeSciences.

How many restricted stock units does Poul Mojdeh hold after this Integra (IART) grant?

After this transaction, the Form 4 shows Poul Mojdeh with 445,691 restricted stock units in the reported award category. This figure reflects her direct beneficial ownership of these derivative securities following the 343,393-unit grant reported in the filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/12/2026 - 05:07 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Poul Mojdeh

(Last) (First) (Middle)

1100 CAMPUS ROAD

(Street)

PRINCETON NJ 08540

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
INTEGRA LIFESCIENCES HOLDINGS CORP [ IART ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
03/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0	03/11/2026		A		343,393		(1)	(1)	Common Stock	343,393	$0	445,691	D

Explanation of Responses:

1. The award was a restricted stock unit award which will vest in three equal annual installments on the first, second and third anniversaries of the grant date of 3/11/2026 and which shall be delivered to Ms. Poul within 30 days following the first business day that occurs immediately following the six month period after the date of her separation of service as deferred compensation. The award is subject to accelerated vesting upon termination of employment by reason of death or disability or upon a qualifying termination on or within 24 months following the date of a change in control.

Remarks:

	/s/ Michael D. Hutchinson; Attorney-in-Fact for Mojdeh Poul	03/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.